Bank of America Securities analyst Travis Steed maintained a Buy rating on Shockwave Medical (SWAV – Research Report) today. The company’s shares closed yesterday at $316.07.
Steed covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Inspire Medical Systems, and Shockwave Medical. According to TipRanks, Steed has an average return of 10.7% and a 70.50% success rate on recommended stocks.
Currently, the analyst consensus on Shockwave Medical is a Moderate Buy with an average price target of $253.29.
The company has a one-year high of $327.73 and a one-year low of $157.00. Currently, Shockwave Medical has an average volume of 571.2K.
Based on the recent corporate insider activity of 108 insiders, corporate insider sentiment is neutral on the stock. Last month, Frederic Moll, a Director at SWAV bought 81,967.00 shares for a total of $49,999.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Shockwave Medical (SWAV) Company Description:
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.
Read More on SWAV:
- M&A News: JNJ Considers Shockwave Buyout
- Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- ShockWave Medical price target raised to $310 from $275 at BofA
- ShockWave Medical price target raised to $286 from $260 at Needham
- ShockWave Medical price target raised to $290 from $275 at Piper Sandler
